Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

被引：0
|
作者：
Fu, Chengcheng [1 ]
Wang, Jing [1 ]
Yan, Lingzhi [1 ]
Jin, Song [1 ]
Shang, Jingjing [1 ]
Shi, Xiaolan [1 ]
Yao, Weiqin [2 ]
Yan, Zhi [1 ]
Wu, De-Pei [1 ]
机构：
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Collaborat Innovat Ctr Hematol,Affiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Hematol, Jiangsu Inst Hematol,Natl Clin Res Ctr Hematol Di, Suzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185263
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
    Voorhees, Peter M.
    Rodriguez, Cesar
    Reeves, Brandi
    Nathwani, Nitya
    Costa, Luciano J.
    Lutska, Yana
    Bobba, Padma
    Hoehn, Daniela
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [2] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
    Nooka, Ajay
    Kaufman, Jonathan
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah
    Anderson, Larry
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas
    Usmani, Saad
    Richardson, Paul
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
  • [3] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [4] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [5] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Ajay K. Nooka
    Jonathan L. Kaufman
    Cesar Rodriguez
    Andrzej Jakubowiak
    Yvonne Efebera
    Brandi Reeves
    Tanya Wildes
    Sarah A. Holstein
    Larry D. Anderson
    Ashraf Badros
    Leyla Shune
    Ajai Chari
    Huiling Pei
    Annelore Cortoos
    Sharmila Patel
    J. Blake Bartlett
    Jessica Vermeulen
    Thomas S. Lin
    Paul G. Richardson
    Peter Voorhees
    Blood Cancer Journal, 12
  • [6] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Shune, Leyla
    Badros, Ashraf
    Chari, Ajai
    Richardson, Paul G.
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Hoehn, Daniela
    Lin, Thomas S.
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
  • [7] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
    Rodriguez-Otero, Paula
    Moreau, Philippe
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Perrot, Aurore
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    van de Donk, Niels W. C. J.
    Schjesvold, Fredrik
    Delforge, Michel
    Einsele, Hermann
    Spencer, Andrew
    Lonergan, Sarah
    Vieyra, Diego
    Sitthi-Amorn, Anna
    Carson, Robin L.
    Blade, Joan
    Boccadoro, Mario
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Rodriguez-Otero, Paula
    Hang Quach
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels
    Katodritou, Eirini
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Blade, Joan
    Moreau, Philippe
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S30 - S31
  • [10] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sara A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Lutska, Yana
    Bobba, Padma
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter M.
    BLOOD, 2020, 136
12345